GALE Galena Biopharma Inc.

0.29
-0.01  -2%
Previous Close 0.30
Open 0.30
Price To book 0.92
Market Cap 13380169
Shares 45,712,912
Volume 82,891
Short Ratio 5.03
Av. Daily Volume 682,492

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171191450
  2. 425 - Prospectuses and communications, business combinations 171191396
  3. 8-K - Current report 171191358
  4. CT ORDER - Confidential treatment order 171186296
  5. 424B3 - Prospectus [Rule 424(b)(3)] 171184861

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2019.
NeuVax in combination with Herceptin
Breast cancer - HER2 3+
Phase 2a data presented March 2017.
GALE-301
Ovarian & Endometrial Cancer
Phase 3 trial terminated due to poor efficacy.
NeuVax (E75) - PRESENT
Low-to-intermediate HER2+ breast cancer
GALE-301 Phase 2a primary analysis presented at ASCO 2016.
GALE-301/302
Ovarian cancer
Phase 2 planned.
NeuVax
Gastric cancer
Phase 2b completion of enrollment announced September 28, 2017 - with interim efficacy analysis due 1Q 2018.
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 3 trial to be initiated late 2017.
GALE-401
Essential Thrombocythemia (ET)
Phase 2 trial initiation announced December 14, 2016.
NeuVax
Ductal Carcinoma in Situ (DCIS)